The morning light itself, the SPF moisturizer ranking's own hero, standing at the head of a Take argued from that Card, because every bottle below is finally a claim about skin in this sun. The frame shows a wearer, not a tube: the photo bank holds no SPF moisturizer product photography, no tube or pump-bottle frames and no bathroom-shelf frames, a gap the ranking names on its own page and the honesty section below admits in full.

Checked and updated October 2026

The thesis: the panel is not on the page

Begin with what the law has already done, because on this shelf it has done everything this column has ever asked a maker to do voluntarily. A sunscreen moisturizer is not a cosmetic with ambitions. It is a drug, filed as a drug, and its carton carries the Drug Facts panel in the federal format: the active ingredients with their percentages, homosalate 10%, avobenzone 3%, zinc oxide 6.3%, the purpose stated, the warnings stated, the directions stated, down to the two-hour reapplication interval. Eight bottles stand on the Card, from the drugstore Cetaphil at $3.60 an ounce to the Kiehl’s at $22.94, and there is not one of them for which this document does not exist. The panel is not a reform to be campaigned for, not a standard a brave maker might pioneer. It is written, filed, printed on cardboard and shipped with every unit. The shelf’s disclosure problem, the problem this whole run of columns has counted in one form or another, has been solved by the state, in advance, for the entire category. What remains is a distribution problem, and it is total: the solved document is not distributed to the one address where the category is now bought.

The count is short enough to quote entire. A full Drug Facts panel on the maker’s own product page: none of eight. Ingredient lists, the weaker document, a cosmetic-style enumeration standing where a panel belongs: published by three makers of the eight, one of them through regional mirrors. One maker’s page, the Eucerin’s, read entire for this record, prints a description and a frequently-asked-questions file and nothing else gradeable: no panel, and also no price and no size, the page withholding even the commerce facts alongside the drug facts. Three maker pages stand unverified in the Card’s record and are counted as not shown, never assumed, a counting rule printed in this issue’s honesty section at full size. So the zero is an honest zero with its method attached: of the pages read, none prints the panel; of the pages unread, none is claimed to. The best-documented shelf in the run, eight doses in public records, eight broad-spectrum banners, full marks for the existence of evidence, and at the point of sale the evidence itself is absent in eight of eight cases. A buyer standing at any of these pages with money in his hand can read everything about the bottle except the one document the law guarantees exists for it.

What the pages print instead deserves its own count, because the absence is not a silence, it is a substitution. Broad spectrum, the panel’s claim, stands on eight of eight pages, promoted from the panel’s small print to the page’s banner line. The reapplication direction, the panel’s instruction, stands in the label directions of seven of eight records, and in the maker’s own copy on two of eight, the winner’s How To Use printing it as Step 2, a category FAQ at another house stating the interval in prose. The moisturizer story stands everywhere: niacinamide seated on three of eight lists, ceramides on three, hyaluronic acid on five, the cosmetic ingredients named, seated and narrated at the length the drug ingredients are not. And the SPF figure itself stands on every page and every carton as the shelf’s one universally printed number, six bottles at 30, one at 50, one at 20, explained as the laboratory ratio it is on none of eight. The pattern across the counts is exact enough to state as a rule of the shelf: everything on the label that persuades has been republished, and everything on it that measures has been left in the filing. The page is not a careless copy of the label. It is an edited one, and the edit runs in one direction, the claims travelling and the numbers staying home.

Take No. 18 is this issue’s parent, and the advance on it is the point of the issue, so it is worth stating both rulings side by side. On the scalp shelf, the dose sorted by filing category with mechanical neatness: the bottles filed as drugs printed their percentages under federal panels, the bottles filed as cosmetics printed none, and exactly one cosmetic dosed voluntarily and won its Card. The law printed the number, there, and the number reached the buyer, because a drug bought in a store carries its panel into the buyer’s hand on the carton he picks up. The SPF moisturizer shelf removes the sorting: there are no cosmetics on it. All eight are drugs, all eight are panelled, all eight doses are filed in public, six of them in the federal label database itself. By the parent issue’s logic this should be the best-numbered shelf in the run at the point of sale. At the point of sale it is numbered nowhere, and the reason is a change of venue the parent issue did not have to face. The compulsion binds the carton. The purchase has moved to a webpage. Between the carton and the webpage the number is under no obligation to travel, and on eight of eight records it does not. The law printed the number. The shelf, which is now a screen, mislaid it in the move, and no one’s filing was harmed in the mislaying, which is precisely what makes it a finding about addresses rather than about honesty in the old sense.

The twist that separates this shelf from every blank this column has counted is that the numbers are public. This is not Take No. 2’s empty column, where the dose existed nowhere a buyer could read it. The doses here exist in the most public documents American commerce keeps: six panels on DailyMed, the federal label library, the seventh record’s doses on its maker’s own published lists, the eighth’s corroborated in the FDA’s directory of drug listings. This desk read all eight from those sources and graded them, which the counter-argument below will rightly say proves the access is real. What it does not prove is that the access reaches the buyer at the moment it would inform him. A filing is addressed to regulators, to pharmacists, to desks like this one: readers who arrive knowing the document’s name, its database and its vocabulary. The man at the product page arrives knowing the product’s name and his own morning. Between those two readers stands the whole distance this issue measures, and it is measured in the record itself, in where each dose stands: a database record, a regional mirror, a retailer’s label copy, a set page inside the maker’s own site that is not the product’s page. Not one of the eight addresses is the page that sells the bottle. The document exists. Its address is wrong, eight times, in the same direction, and a fact that can only be found by leaving the shop is, for the purposes of the purchase, a fact the shop does not carry.

The record supplies one proof that the address, and not anything deeper, is the failure, and it is the shelf’s saddest document, sadder than any blank in the run because the blank here is flanked by printings. The sent-home bottle’s maker currently publishes two panels for it. On one of its own pages, a set page, the house prints the current formula’s doses, avobenzone 2.2% and octocrylene 9.5%, the reformulation the federal directory dates to June 2025. On another of its own pages, and at its largest door, the same house prints the retired panel, avobenzone 2.2% and octinoxate 7.5%, the very document this desk graded on two earlier Cards. The house can publish doses on a webpage; it does, in two versions, one of them obsolete. What it does not publish is the panel, the senior document that would tell a reader which of its own pages to believe. And the winner’s record makes the same point from the top of the table: the CeraVe’s current formula stands in three versions in current records, the maker’s filing, a warehouse variant with one filter swapped and the zinc raised, and a stale panel at the door the Card links, that door standing valid for price and stock and explicitly not for the panel. Where the canonical document is not republished at the point of sale, every lesser republication drifts, in the maker’s own house as readily as at retail, and the drift is documented by the documents themselves. The filing is the only fixed point on the shelf, and it is the one text the shelf’s pages do not carry.

Nothing on this page is scored. Every score quoted here, every row, every price and every count is the SPF moisturizer ranking’s, Verdict Card No. 109, reproduced exactly as that Card published it: the CeraVe AM at 82, the La Roche-Posay Double Repair UV at 81, the Olay Complete at 79, the Kiehl’s Ultra Facial Cream with Sunscreen at 76, the Neutrogena Hydro Boost SPF 50 at 75, the Cetaphil DermaControl at 74, the Eucerin Immersive Hydration at 68, and the Jack Black Double-Duty sent home at 56, re-graded in the open from 71 and 45 on its two earlier bases. The only arithmetic of this page’s own is addressing: where each of the eight doses stands, what stands on the page instead of it, and how far a buyer must travel from the till to reach the document the law already wrote for him. The brief for this issue carried the record’s counts, and they survived the record in their spine; the precisions the record adds, about the reapply count’s two tiers, about the one record with no federal database entry, and about the zero being a count of pages shown with three pages unverified, are stated in the honesty section rather than absorbed, because a column about the distance between a filing and a page should be exact about its own distances.

The record, counted

Start with existence, because this shelf inverts the run’s usual census. On shelf after shelf this column has counted what exists: lists on some, doses on fewer, panels almost nowhere. Here the existence column is full. Eight bottles, eight drugs, eight complete panels in existence, eight doses standing in a public record, broad spectrum printed on eight of eight cartons and pages alike. The federal database holds six of the panels outright. The Cetaphil’s doses stand on its maker’s own published lists, active and inactive, and in no DailyMed record the desk could find, the shelf’s exception in kind: its panel exists on its carton by the same law, but the practical route to it, the database search, does not reach it, and a buyer armed with this column’s method would find seven records where the shelf holds eight and reasonably conclude the eighth was never filed. The Jack Black’s current doses stand on its maker’s set page, corroborated by the FDA’s NDC directory, against the retired panel its other page prints. So even the existence column has a geography: six doses at the federal library, one at the maker’s lists alone, one at a set page and a directory, and none of the eight at the shelf. The most public documents in American retail, and their addresses are a database, a mirror and a bundle page. The product page is the only address on the list that a buyer visits uninvited, and it is the only one carrying nothing.

The doses themselves, counted as loads, deserve the paragraph the pages deny them, because the shelf’s spread is wide and entirely invisible at the point of sale. Total filter load, as filed: the Neutrogena at 31.5% on its newer record, the CeraVe at 28.3%, the Eucerin at 27.5%, the La Roche-Posay and the Kiehl’s at 20% each, the Olay at 19.4%, the Cetaphil at 15%, the sent-home Jack Black at 11.7%. The dearest bottle’s load stands mid-table and the cheapest ounce’s stands lowest but one, and no arrangement of the prices predicts the arrangement of the loads, as no arrangement of them has predicted anything on any shelf in this run. Two of the records stand in two versions at once inside the federal record itself: the Neutrogena in two listings, homosalate at 15% and at 13.5%, the older filing’s total at 33% against the newer’s 31.5%, and the CeraVe, beside its filing, in the warehouse variant and the stale door panel counted in the thesis. The filings are the shelf’s bedrock and they are not bedrock still: they are revised, superseded and re-filed like every other document in this run, which is one more reason the desk grades the filing and prints the version it graded, the CeraVe on the December 2023 label, the Olay on the July 2026 record, the Neutrogena on the September 2025 filing. A buyer reading casually at the database would meet the plurality without the grading. A buyer reading at the page meets nothing at all. Between those two failures of address, this desk’s is the one that says which document it is standing on.

The cosmetic half of the record is counted beside the drug half because the pages themselves insist on the comparison, printing the one and withholding the other. Niacinamide stands seated on three of eight lists, at the head of the winner’s inactives, fourth on the Olay’s, fifth on the La Roche-Posay’s. Ceramides stand on three of eight. Hyaluronic acid, in one form or another, stands on five of eight, and its absences are as documented as its seats: the La Roche-Posay’s non-UV sibling seats it and its UV record drops it, claiming it nowhere, an honesty the Card credits on the record with the shelf’s highest honesty row. Fragrance filed as Parfum stands on none of eight, a clean column this run rarely gets to print, the scented skip carrying its scent as named oils at twenty-eighth, twenty-ninth and thirty-fourth. Alcohol denat. stands on two of eight, second on the Eucerin’s list, a fact its maker’s page, which prints neither the list nor the panel, leaves entirely to the filing. Zinc oxide is dosed on two of eight, both hybrids, the CeraVe’s 6.3% and the Olay’s 6.9%, and an all-mineral panel stands on none of eight, against which the winner’s own copy foregrounds its one mineral filter of five under a technology name, and a brand answer at its door calls the bottle a mineral sunscreen outright. The filings correct the copy in every one of these particulars. The filings are also the only place the corrections exist.

The ritual column closes the census, and it is the column where the pages’ selectivity is easiest to see because the ritual is the label too. The two-hour reapplication direction is a Drug Facts direction, part of the same panel as the doses, and it stands in the label directions of seven of eight records: the winner’s maker prints it in its own How To Use as Step 2, one house states it in a category FAQ’s prose, the Eucerin’s stands in its filed Directions while its maker’s page FAQ, prescribing morning use as the routine’s last step, omits it entire. The one maker-page exception in the other direction completes the shape: the sent-home bottle’s directions print the application and no reapplication at all, the only record on the shelf whose own document retires the ritual after the first act, on the bottle with the shelf’s lowest SPF figure, under the floor this site’s skincare routine prints. And one record’s maker directions deviate from the standard in the open, the Cetaphil prescribing application about twenty minutes ahead and reapplication, in its word, frequently, the US-standard wording standing only in retailer label copy. So the direction is treated by the shelf’s pages the way the direction’s own contents suggest: printed where it flatters the ritual, softened where a house prefers its own words, omitted where it complicates the sale, and in every case severed from the panel that gives it its authority, the doses and warnings it was filed beside. The label arrives at the page in pieces, and the pieces are chosen.

The value column, last as usual, refuses as usual to redeem the pattern. The shelf’s dearest ounce is the Kiehl’s at $22.94, its panel standing on the federal record and two doors’ agreement, its maker’s own product page unreadable in the Card’s pass and counted, in the panel census, as not shown. The cheapest ounce is the Cetaphil’s at $3.60, the record whose panel stands in no federal database at all. The winner sells at $6.66 an ounce through a door that prints a superseded version of its panel, the desk marking the door valid for the price and the stock and not for the document. The Eucerin’s only price in the record is a grocery-delivery listing’s offer figure, its card pill-less, its maker’s page declining to state what the bottle costs in the same breath as it declines to state what is in it. Price, on this shelf as on every shelf before it, sorts by the houses’ altitudes. The panel sorts by nothing: it exists at every altitude, complete, standardized, free to read in a federal library, and absent at every altitude from the page where the altitude is charged. Of all the columns this desk has counted, this is the first in which the missing document is missing at no one’s convenience but the page’s, the law having already paid the entire cost of producing it.

What the missing panel costs

The first cost is comparison, in a new form, because here comparison is not defeated by scarcity but by geography. On the earlier shelves the buyer could not compare doses because the doses were not published; his errand ended at a wall. Here the doses are published, standardized by a federal template into the most comparable documents in the whole grooming run, eight panels in one format, loads running 11.7% to 31.5%, and the buyer still cannot compare them at the place where comparison happens, because the format lives in a database and the shopping lives on a page. He can compare the claims, which are unstandardized by design. He can compare the prices, the sizes, the stories. He can compare the one number the law allows to double as an advertisement, the SPF badge, whose basis no page explains. The single comparable column the category possesses is the single column the point of sale omits, and it is omitted uniformly, by the discounters and the prestige houses alike, which is how a buyer knows the omission is a convention of the page rather than a failing of any house. Conventions are not answered by any one maker defecting, as this column has had cause to print before; but conventions are named by being counted, and this one now has its count: the panel, none of eight.

The second cost is drift, and the shelf documents it at both ends of the table. A document that is not republished at the canonical address does not stay pure in its filing; it leaks into circulation in copies, and the copies age at different rates. The winner’s formula stands in three versions in current records, and a buyer who does the work, leaves the page, finds a panel for the bottle at its own door, will read the stale one and never know it, the door printing homosalate at 12% and zinc at 3.5% for a bottle whose graded filing reads 10% and 6.3%. The skip’s maker prints the retired panel on one of its own pages in the present tense, so the work of checking is rewarded there with the wrong answer from the horse’s own mouth, and only the federal directory, read with the desk’s habits, reveals that the house’s other page is the current one. Even inside the federal record, two of the eight stand in plural versions, their loads differing by points between filings. The panel’s absence from the page is therefore not a tidy withholding of a settled text. It is the removal of the one fixed point against which every circulating copy could be checked, and the shelf’s documents, unanchored, have drifted exactly as unanchored documents do: quietly, in the direction of whichever version was already typeset. The filing is senior to all of them. Seniority that must be discovered in a directory is a legal fact, not a reading experience.

The third cost is the habit the shelf teaches, and it compounds past the category, as the scalp shelf’s habit did in Take No. 18. A buyer trained by these eight pages learns the shape of a drug’s page as a story with a badge: the ritual in the morning light, the technology names, the seated cosmetic ingredients narrated like characters, and at the end a number whose meaning is a feeling of altitude, 30, 50. He learns that the dose is a database’s business, a matter for regulators and for desks that grade documents, and that the label, whose face he will hold in his hand exactly once, at the unboxing, after the money has moved, is a source of slogans to be previewed and numbers to be skipped. The houses learn the matching lesson from their side: that the panel’s production, which the law exacts from them in full, buys them nothing at the point of sale, and that the page’s edited label, claims forward and numbers home, is the equilibrium no competitor is punished for keeping. The one volunteer-shaped space on this shelf stands empty in a way it never stood on the scalp shelf: no house at any altitude has yet defected by printing the whole panel where the bottle is sold, though the document is written, the format is free, and the first defector would own the shelf’s honesty column outright, as the volunteer owned the scalp ranking’s. The offer this column makes to every shelf applies here in its cheapest form ever: the document exists; the defection costs a paste.

The other side, stated fairly

The case against this Take is a serious one, and it runs in four parts. First: nothing is hidden from the person who matters. The panel is printed on the physical carton the buyer receives, in full, in the federal format, and it is read at the moment it governs, the morning application, by the person whose skin it governs. An online product page is a shop window; the carton is the document, and the document is delivered with the goods, unabridged, every time, which is more than this column can say for most of the documents it grades. Second: web pages are marketing surfaces, not labels, and the distinction is the law’s own. Regulation governs the label because the label is the controlled text; no rule requires a maker to republish his panel on a product page, and a page rebuilt as a legal panel, warnings and all, would serve neither the shopper scanning at speed nor the regulator whose format assumes card stock. Every regulated industry works this way; the grocer’s website is not a nutrition panel either. Third: the filing is genuinely public. The FDA’s databases, DailyMed and the NDC directory, are free, searchable and complete for their purpose, and this desk’s own work proves the access: every dose in this issue was read from public sources in an afternoon. Publication in a federal database is publication, and a column that calls it secrecy has confused its own convenience with the public’s. Fourth: a percentage lifted onto a page, severed from the panel’s warnings, directions and context, would mislead more than it informs, the misreading Take No. 15 warned against, buyers doing cross-bottle arithmetic on loads that are not efficacies, 31.5% read as twice the product of 15%, so the panel’s absence from the page may be the more responsible typography.

Each part is true about something, and the record answers each on its own ground. To the carton: conceded that the panel arrives with the goods, complete, and printed in this issue’s first paragraph as the law’s finished work. But a purchase is not informed by a document delivered after it. The decision this shelf exists to serve, which of eight dosed bottles, at loads from 11.7% to 31.5% and ounces from $3.60 to $22.94, happens at the page, with the carton still in a warehouse, and a document that can only ratify a decision is a receipt, not a record. The carton’s completeness is exactly what this Take praises; its timing is what it charges. Nothing in the defence explains why the document that is complete enough for the bathroom is too complete for the till, when the till is where its comparisons would be spent.

To the marketing-surface limb: agreed that no rule requires republication, and this Take brings no legal charge, says so in its honesty section, and grades the omission as a convention rather than a violation. But the defence proves too much for the pages it defends. These are not bare shop windows. They publish ingredient lists, three makers of them; they publish directions, prices, sizes, warnings of a commercial kind, claims in the dozens, and the label’s own claim, broad spectrum, promoted to the banner on eight of eight. A surface that republishes the label’s persuasive half at length has waived the argument that labels are not its business. What remains is a choice of which half, and the choice is uniform and legible: the half that persuades travels, the half that measures stays. Nor does the format argument carry: nothing in any rule forbids a maker from printing his panel on his page either, and one house on the shelf already prints a label direction in its own how-to copy, in context, voluntarily, which is the panel’s instinct at one remove. The page is a label surface when the label sells. This Take simply prints the exchange rate at which it stops.

To the public-database limb, the strongest of the four on paper: conceded, and demonstrated by this desk’s own afternoon, that the filings can be read. The answer is in what the reading found. The database route requires a buyer to know that the document exists, that it lives in a federal library, and that his bottle’s labeler files under a corporate name not always the brand on the tube; and on this shelf the route fails in its strongest form twice. One record stands in no DailyMed record at all, its doses reachable only through its maker’s lists, so the database method, diligently applied, reports a blank for the Cetaphil and invites exactly the false conclusion the method exists to prevent. And the eighth record’s database trail leads to a bottle whose own maker prints two panels in two places, the directory corroborating the newer while the maker’s better-known page prints the older, so the searching buyer meets a contradiction the database alone does not senioritize for him. Publication in the legal sense, secrecy in the practical one, is not a paradox this Take invented for rhetoric; it is the shelf’s own census, eight public doses whose public cannot find two of them reliably and the rest only by leaving the shop with a librarian’s errand in hand. A filing is addressed to the state. The page is addressed to the buyer. This issue is about the second address having nothing in it.

To the context limb: agreed that a bare percentage, stripped of its panel, invites bad arithmetic, and the desk’s counts are built to refuse that arithmetic, loads printed as loads and never as efficacies, here and on the Card. But the defence aims at a remedy this Take does not propose. The ask is not for percentages pasted into banners; it is for the panel, the whole document, doses with their warnings and directions together, the format the law designed precisely so that a number arrives with its terms attached, readable by the reader it was formatted for. The shelf already proves the appetite for the format exists at the page: the direction half of the panel is republished piecemeal because makers judge, correctly, that buyers use it. The whole panel is that instinct completed, and its absence is not a typography of care. It is the equilibrium of a surface on which the numbers are the only part of the label with no one to speak for them, the claims having the marketing department and the doses having a database.

The picks, as published on the Card

The discipline for using any of them is the Card’s, unchanged: read the dose at its filing before the claim at its page, ask where every number you are shown is addressed from, and treat a page’s story as copy until the panel cashes it. The standing offer of this column applies to the shelf in its own terms, and on this shelf it is the cheapest offer the column has ever made: the first maker to print his full Drug Facts panel on the page that sells the bottle, the document already written, already formatted, already shipped in every carton, will be named here, at the top of a re-argued column, the same day its page can be read. No new document needs inventing, no percentage needs volunteering, no standard needs adopting. The panel exists in every maker’s files, in the federal library, in the warehouse on the cardboard. On this shelf it is simply never addressed to the buyer, and the pages travel without it.

What this page does not claim

On the evidence. This page scores nothing and tests nothing. Every score, row, price, dose and count is Verdict Card No. 109’s, reproduced exactly as that Card published it, and the Card’s own evidence discipline stands behind it: the desk grades published documents, federal filings as filed and maker pages as read, makers’ claims graded as claims, prices per ounce with the arithmetic printed, and asserts nothing about what any filter does on any skin. No application or wear testing stands behind anything here, the Card’s printed discipline and this issue’s. The counts this Take adds, the panel standing on none of eight maker pages, the doses standing in a public record on eight of eight, the reapply line’s two tiers, are counts of the Card’s printed record and are printed as counts so they can be recounted. Where the Card’s record rests on a document that moves, the graded version is the one named: the CeraVe on its December 2023 filing against the warehouse variant and the stale door panel, the Olay on its July 2026 record against the circulating UV365 label, the Neutrogena on its September 2025 filing against the older listing, and the Jack Black on the current panel its maker’s set page and the federal directory agree on, against the retired panel its other page and its door still print.

On the brief’s premises, checked against the record. This issue was briefed on the Card’s panel census, and the census survived the record in its spine, which the honesty section prints because the column’s habit is to print its confirmations and its corrections in the same place. Survived: every bottle on the shelf an over-the-counter drug carrying a complete panel by law; the panel in Drug Facts form on none of the eight makers’ selling pages; the doses standing in a public record on eight of eight; the two-hour line standing in seven of eight label directions. Three precisions the record insists on, printed rather than absorbed. First, the seven is a label-directions count with two tiers beneath it: in the makers’ own copy the line stands on two of eight, and one of the seven, the Cetaphil’s, stands only in retailer label copy, its maker’s own directions deviating from the standard with a twenty-minute application and reapplication prescribed as, in its word, frequently. Second, the universality of the federal route has one exception in kind: no DailyMed record was found for the Cetaphil DermaControl, so the practical address for its panel is its maker’s published lists and its carton, and the eighth record’s panel stands corroborated by the FDA’s NDC directory and its maker’s lists rather than filed where the other six stand. Third, the zero is a count of pages shown: three maker pages, the Kiehl’s, the Olay’s for the exact product and the Neutrogena’s, stand unverified in the Card’s record and are counted as not shown, never assumed, the five read pages printing ingredient lists at best from three makers and, at the Eucerin’s, neither panel, price nor size. The charge is therefore stated at its exact strength: on no page the desk could read does the panel stand, and the pages it could not read are named.

On what SPF moisturizers do. Nothing on this page says any bottle protects, hydrates or suits any face well or badly, and nothing says a higher filter load is a better product: the loads counted here, 11.7% to 31.5%, are documents, quantities of named filters as filed, and are graded as documents, never as efficacies, the desk’s standing rule on every shelf where a percentage can be mistaken for a result. The SPF figure is quoted throughout as what it is, a laboratory ratio printed as a badge, its explanation standing on none of the eight makers’ pages and supplied by no sentence of this one beyond naming it. What is graded is the paper the buyer is handed at each address: whether the panel is republished where the bottle is sold, where the dose stands instead, whether the circulating copies agree with the filing, and what the ounce costs against what its page discloses. The desk opened no tube and stood in no sun for this issue. The argument is about what is printed for a reader to read before the purchase, and on eight records what is printed at the purchase is the label’s persuasive half, the whole of the label standing in a federal library the purchase never visits.

On the photographs, and on the record moving. There are no photographs of ranked products on this page because there are none to print: the photo bank holds no SPF moisturizer product photography, and no grooming product or bathroom-shelf photography of any kind, a gap the ranking names on its own page, and the hero and figure here are frames of the subject itself, the ranking’s own hero and a portrait at examining distance, captioned for what they show, which is a wearer, not a product. The record itself moves underneath this argument: the winner’s formula stands in three versions in current records and its door’s panel is owed a re-read in the November pass; the sent-home bottle’s reformulation is dated June 2025 in the federal directory while its maker’s pages still disagree about which panel is in the bottle; the Neutrogena stands in two federal listings at once and the Olay’s current record is dated July 2026 against a superseded label still in circulation; the Eucerin’s door could not be verified at a shelf and its card stands pill-less, owed a door in the same pass. The scores and the rule stand as published until a cited record changes; when one does, the Card moves first and this Take is re-argued from it, in the open.

Questions, answered from the record

Next

The record this issue argues from stands in full at the SPF moisturizer ranking, Verdict Card No. 109, where every filing quoted here is printed with its version named and every bottle carries its own card. The shelves around it are the two it stands between: the moisturizer Card, No. 66, where the winner’s plain sibling was graded without the drug document, and the sunscreen Card, No. 68, where the panels were graded as the shelf’s furniture, and the routine that prints the shelf’s SPF 30 floor stands at the skincare routine. The kinship runs three ways: Take No. 18 is the parent argument, the law prints the number, since there the scalp shelf’s dose sorted by its filing, four bottles numbered because they were drugs and the prestige cosmetics blank because they were cosmetics, and the number reached the buyer because a drug’s panel travels with its carton to the shelf, while here every bottle is a drug, the panel exists for all eight and the doses stand filed in public, and the number still does not reach the buyer at the point of sale, the purchase having moved to a webpage the compulsion does not govern, so that the law printed the number entire and the shelf mislaid it between the filing and the page; Take No. 13 is the grandparent, the copy is not the list, since there the maker’s copy was graded against the maker’s own list and the list won, while here a third document stands senior to both, the panel the state wrote, and the page prints the copy, sometimes the list, and the senior document nowhere, the contest no longer between two of the maker’s texts but between all of them and the filing; and Take No. 21 is the nearest sibling, the clay stands third, since there the shelf printed its evidence entire, eight lists in descending order standing on the makers’ pages for any buyer to count, and the names failed inside the evidence itself, while here the shelf prints its marketing entire and its evidence nowhere at the point of sale, the doses existing complete in a federal library the purchase never visits, so the failure has moved from inside the document to the document’s address. The franchise so far: No. 1, grooming is sold by the step and works by the habit; No. 2, the number nobody prints; No. 3, one tube, two honesties; No. 4, the pair graded as one record; No. 5, the name is not the number; No. 6, the name is not in the list; No. 7, the number is not the dose; No. 8, the minute is the dose; No. 9, the ritual is not an ingredient; No. 10, the hold is an adjective; No. 11, the name is not an ingredient; No. 12, the burn is not the proof; No. 13, the copy is not the list; No. 14, the number is in another country; No. 15, the rinse is not the dose; No. 16, the step is not a species; No. 17, the oil stands fifth; No. 18, the law prints the number; No. 19, the technology is not dosed; No. 20, the figure is not a scale; No. 21, the clay stands third. How every score on this site is built is set out in the methodology. The Takes continue by number; the next one starts, as this one did, from a record that already exists or a blank that is printed as one.